Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587716 | 0.89 | SMN1; SMN2 (0.47) | HPGDSMN1; SMN2TSHRMAPTALPL | |
| SCHEMBL14587717 | 0.86 | SMN1; SMN2 (0.46) | HPGDSMN1; SMN2TSHRMAPTNPC1 | |
| SCHEMBL14587718 | 0.81 | GAA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL14587715 | 0.81 | TSHR (0.48) | HPGDSMN1; SMN2TSHRMAPTNPC1 | |
| SCHEMBL3822963 | 0.80 | PYGL (0.50) | HPGDSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL13933580 | 0.80 | HPGD (0.41) | HPGDSMN1; SMN2TSHRMAPTALPL | |
| SCHEMBL5008490 | 0.79 | NPC1 (0.67) | HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14587751 | 0.79 | HPGD (0.40) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL14587721 | 0.78 | AVPR2 (0.49) | SMN1; SMN2RAB9A | |
| SCHEMBL13933418 | 0.78 | GRM5 (0.41) | SMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | HPGD 3765/4885SMN1; SMN2 4705/4885TSHR 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.